Deerfield Agency Acquires Verge Scientific Communications

Published on :

Deerfield Agency, one of the fastest growing independent marketing and commercialization partners for life sciences companies, today announced the acquisition of Verge Scientific Communications, a Virginia-based, brand strategy and strategic communications agency dedicated to shaping the stories of emerging and pioneering health and science-driven companies. With the addition of Verge Scientific, Deerfield Agency is expanding its services and ability to support corporate and brand marketing for pre-commercial healthcare clients, along with deepening experience in branding, strategic communication, scientific and medical communications, and storytelling.

Polaris Genomics Announces Continued Research & $100K Grant Awarded from Maryland Industrial Partnership Program (MIPS)

Published on :

Pricing
Distribution
Press Releases
Newswires
Knowledge Base
Questions? +1 (202) 335-3939 Pricing & Comparison Chart Contact Log InSubmit Release
World Media Directory · RSS · Email Newsletters
There were 240 press releases posted in the last 24 hours and 209,946 in the last 365 days.
Polaris Genomics Announces Continued Research & $100K Grant Awarded from Maryland Industrial Partnership Program (MIPS)
NEWS PROVIDED BY
Polaris Genomics
July 19, 2022, 16:38 GMT
SHARE THIS ARTICLE
As we continue to set our sights on better serving veterans, frontline workers & trauma-impacted communities, MIPS grants leverage crucial funding that accelerates genomics research outcomes.”— Polaris Genomics CEO Charles CathlinROCKVILLE, MD, UNITED STATES, July 19, 2022 /EINPresswire.com/ — The biotech startup that brought to light the first and only PTSD genomic test announces continued research and innovation with continued funding from a second $100,000 matching grant awarded by the Maryland Industrial Partnership Program (MIPS).
In the Fall of 2020, Polaris Genomics was awarded a $100,000 matching grant by MIPS and began partnering with researchers at the University of Maryland Baltimore to test the performance of PTS-ID, a genomic blood test to identify persons with PTSD, measure disease severity and detect treatment response.
“It was an exciting…

Cutting-Edge Gene Therapy Treatments Being Developed in Montgomery County, Maryland

Published on :

Cutting-edge gene therapy treatments being developed in Montgomery County, Maryland
Nick Iannelli
June 9, 2022, 3:04 PM
share on facebook
share on twitter
share via email
print Listen now to WTOP News WTOP.com | Alexa | Google Home | WTOP App | 103.5 FM
It wasn’t long ago that “gene therapy treatment” sounded like science fiction, but it has now become a reality and cutting-edge work in the field is being carried out in Montgomery County, Maryland, by REGENXBIO, a leading clinical-stage biotechnology company that seeks to improve lives through the curative potential of gene therapy.
“Our products are designed as medicines that deliver genes to cells to address genetic defects or to enable cells to produce therapeutic proteins in the body that are intended to impact underlying diseases,” explained Ken Mills, the President and CEO of REGENXBIO.
The company’s products in clinical development are meant to provide long-lasting effects, potentially altering the course of a disease.
REGENXBIO is currently developing gene therapy products for the treatment of retinal, metabolic and neurodegenerative diseases.
“In some cases, the therapy is delivered through a simple intravenous infusion, maybe for a few hours,” Mills explained. “Patients enter the hospital, receive the infusion and…

Q2 Update by PQE Group: Two Acquisitions’ Announcements with United Pharma Technologies Inc. & Quintian Pharma, and New Offices in Australia and Argentina

Published on :

The first half of 2022 has closed highly positively for PQE Group, the global women-owned quality consulting company for Lifesciences. The Italian parent Group, after having concluded 2021 with + 20% increase in revenues, confirms its development plan with the announcement of two acquisitions and a new legal entity in Melbourne (Australia) and a new office in Buenos Aires (Argentina).

BioFactura Receives BARDA Funding for Smallpox Antibody

Published on :

For more than 40 years, smallpox has not been a viral concern for the world. No cases have naturally occurred since 1977. Despite that, government agencies are worried that smallpox could become a biological weapon in the hands of terrorists and rogue states and are making preparations for such a scenario by stockpiling old medications that have been successful, as well as new, experimental therapies.

BioFactura Announces Activation of a $15.9M Contract Option for its Smallpox Biodefense Therapeutic

Published on :

BioFactura today announced its second contract option activation of $15.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance development of an antibody cocktail therapeutic for the treatment of smallpox.

Baltimore startup raises $3.5M as it prepares to seek FDA approval for new pneumonia test

Published on :

Baltimore startup raises $3.5M as it prepares to seek FDA approval for new pneumonia test Email Facebook LinkedIn Twitter Share article
Pearl Diagnostics, led by founder Kieren Marr, raised a $3.5 million seed round.
Courtesy of Pearl Diagnostics
By Matt Hooke – Reporter
July 18, 2022, 07:13am EDT
A Baltimore medical company that aims to make it easier to diagnose a deadly type of pneumonia raised $3.5 million in an oversubscribed seed round.
Pearl Diagnostics, led by Johns Hopkins University Professor Kieren Marr, plans to use the funding to focus on manufacturing, in preparation for the commercial launch of its urine antigen test for fungal pneumonia. The test is already approved for sale in Europe and the company is currently seeking approval in the United States as well. Pearl plans on submitting its test for FDA approval at the end of this year.
Pearl Diagnostics previously earned around $5 million from the Maryland Technology Development Corp. (TEDCO), the National Science Foundation, the National Institutes of Health and the Cystic Fibrosis Foundation. The company, originally called Mycomed Technologies, has been headquartered at the FastForward U incubator at Johns Hopkins University. The company originally sought to raise $2.5-$3 million. The round closed…

Delfi Diagnostics Announces $225 Million Series B Financing to Develop Globally Accessible Portfolio of Liquid Biopsy Tests

Published on :

This round of financing was led by DFJ Growth with participation from Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, and all existing investors including Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, and Windham Venture Partners.

BD Completes Acquisition of Parata Systems

Published on :

Parata advances BD’s transformative solutions strategy by providing a portfolio of innovative pharmacy automation solutions that power a growing network of pharmacies to reduce costs, enhance patient safety and improve the patient experience for retail, hospital and long-term care pharmacies. As a combined company, BD is positioned to offer a comprehensive set of technologies to the $600 million pharmacy automation market segment that is expected to grow approximately 10% annually to $1.5 billion in the U.S. alone over 10 years.

Materic and LaunchPort Announce Partnership to Drive Advanced Materials Manufacturing for Medical Device Technology

Published on :

Materic and LaunchPort Announce Partnership to Drive Advanced Materials Manufacturing for Medical Device Technology
Jul 17, 2022
Materic’s expertise in advanced materials and 3D printing to combine with The LaunchPort’s skills in GMP production of medical devices and technologies
 
July 18, 2022, Baltimore, MD – Materic, a custom manufacturer of advanced materials, and LaunchPort, LLC, a medical device venture center and GMP contract manufacturing operation today announced a partnership to drive the use of advanced materials in the development of emerging medical device technologies.
Under this new partnership, the two companies aim to combine their respective areas of expertise – Materic in advanced materials processing and The LaunchPort in the GMP production of medical devices and personalized medicine technologies – to accelerate medical device application development across an array of products.
“GMP production doesn’t just require specialized facilities but also people with specialized skills. LaunchPort is a leader in both,” said Ken Malone, Chief Executive Officer with Materic. “We receive a lot of requests from our customers to provide materials made under GMP and this partnership with LaunchPort will allow us to meet their needs efficiently.”
“Over the past decade, the expectations for additive manufacturing in medical devices have been…